A Phase II Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Bavituximab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Peregrine Pharmaceuticals
- 08 Sep 2011 Results were reported in a Peregrine Pharmaceuticals media release.
- 16 Jun 2011 Results were reported in a Peregrine media release.
- 23 Mar 2011 Actual end date (July 2010) added as reported by ClinicalTrials.gov.